LifeScan has reported long-term results for its OneTouch Select Plus blood glucose monitoring platform evaluated over three years in multiple studies involving diabetes patients.
Findings cover more than 21,000 blood glucose meter readings from more than 200 different test strip batches that were launched since the introduction of the OneTouch Select Plus in 2015.
The monitoring system was observed to be accurate and consistent, with an average of 97.6% of results within specification.
LifeScan published the results in Journal of Diabetes Science and Technology.
OneTouch Select Plus is part of the company’s OneTouch portfolio of blood glucose meters, test strips or apps, which also includes OneTouch Verio Flex, OneTouch Verio and OneTouch Verio IQ.
LifeScan Worldwide Medical Affairs senior director David Shearer said: “Self-monitoring of blood glucose is still the most accurate, effective and accessible way people with diabetes can track their blood sugars.
“With the OneTouch Select Plus and the OneTouch Verio range of blood glucose monitoring systems, we are proud to offer people with diabetes and their care teams very accurate products that they know they can trust.”
The company has so far conducted several studies to validate the accuracy of its OneTouch blood glucose monitoring systems.
A study conducted in March last year assessed three lots of the OneTouch Verio Flex blood glucose monitoring system.
In April 2017, LifeScan published seven-year data of the OneTouch Verio platform across more than 70,000 clinical data points in the Diabetes Science and Technology journal.
LifeScan was part of Johnson & Johnson, which sold the blood glucose monitoring products maker to private investment firm Platinum Equity last year.